Search
  1. Home
  2. Southern Africa
  3. South Africa
  • News

Glaxo AIDS drug price probe proceeds

    JOHANNESBURG

    Investigations by South Africa's Competition Tribunal into the pricing of GlaxoSmithKline's (GSK) anti-AIDS drugs will proceed, despite GSK citing a complaint by the US-based AIDS Healthcare Foundation (AHF) as "unfounded and without merit".

    The foundation, which runs an AIDS clinic in KwaZuluNatal Province, lodged the complaint early in 2003, saying Glaxo's high drug prices were preventing the treatment of more HIV-positive South Africans.

    The tribunal heard the complaint earlier this year, and ordered GSK to pay AHF's legal costs.

    AHF president Michael Weinstein said in a statement: "If, as GSK claims, it's done nothing wrong, it should be showing the world why, or even if, it did not violate the law with its AIDS drug pricing in South Africa."

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join